Capitate shortening osteotomy is emerging as a significant surgical intervention for Kienböck's disease, particularly in its early stages. This systematic review consolidates data from three decades of research to evaluate its clinical efficacy. Specifically, the procedure aims to decompress the lunate bone by reducing the axial load through the central column of the wrist. By shifting this mechanical stress, surgeons hope to facilitate lunate revascularization and prevent further carpal collapse. Patients with Lichtman stage 2 or 3A are the primary candidates for this joint-leveling alternative. Consequently, understanding the long-term functional outcomes and potential risks is essential for modern orthopedic practice.

Clinical Benefits of Capitate Shortening Osteotomy

The review identifies substantial improvements in patient-reported outcomes following the procedure. For instance, visual analogue scale (VAS) scores for pain significantly decreased in most study cohorts. Furthermore, the Disabilities of the Arm, Shoulder, and Hand (DASH) scores showed a marked reduction, indicating better daily function. Notably, many patients regained significant grip strength and range of motion. Therefore, capitate shortening osteotomy serves as a robust option for those seeking symptomatic relief without more invasive salvage procedures. However, the success of the operation often depends on the initial stage of the disease at presentation.

Revascularization and Progression Risks

Radiological outcomes provide a mixed but generally positive outlook on the lunate's health. Interestingly, approximately 78% of patients across selected studies showed signs of lunate revascularization after the surgery. This finding suggests that unloading the bone can indeed trigger a healing response in the necrotic tissue. Despite these gains, the disease progression rate remains a concern at roughly 10.9%. Consequently, surgeons must maintain a high level of vigilance during post-operative follow-ups. Additionally, identifying specific risk factors for failure will be vital for improving future surgical success rates.

Frequently Asked Questions

Who is the ideal candidate for capitate shortening osteotomy?

The best candidates are typically patients in Lichtman stage 2 or 3A who have neutral or positive ulnar variance. These individuals often see the most significant pain reduction and functional improvement.

How successful is lunate revascularization after this procedure?

Current research suggests a revascularization rate of nearly 78%, which is highly encouraging for preventing further bone collapse and joint degeneration.

What are the primary risks associated with this surgery?

While pain reduction is common, there is a persistent failure rate of about 10.9%. Patients may still experience disease progression, requiring careful monitoring or potential secondary procedures.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Simske N et al. Capitate Shortening Osteotomy for Kienböck's Disease: A Systematic Review. Hand (N Y). 2026 May 10. doi: 10.1177/15589447261441826. PMID: 42106954.

Lichtman DM, et al. Kienböck Disease: Moving Forward. J Hand Surg Am. 2016;41(5):630-638.

Almquist EE. Capitate shortening in the treatment of Kienböck's disease. Hand Clin. 1993;9(3):505-512.